Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Asia Pacific

Germany says production capacity, not patents, key to upping vaccine output

1 minute read

The main challenge to raising production of COVID-19 vaccines is how to quickly and effectively transfer technology, Germany's health minister said Friday, reiterating Berlin's opposition to a U.S. proposal to waive patent protection.

"The main issue is not patent protection but production capacity," Jens Spahn told a news conference on Friday.

In a jab at the Biden administration, Spahn also said: "I would be delighted if the United States shows the same willingness to export vaccines that we in Germany do."

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters